A Multicentre, Double-blind, Randomized, Placebo Controlled, Parallel Group, Phase 3, Safety Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma (DESTINATION)

drug protocol number

D5180C00018

drug sponsor

AstraZeneca

drug study

Tezepelumab

drug trial site

King Abdulaziz University Hospital (Jeddah), King Abdulaziz Medical City NG (Riyadh)

drug status

Ongoing

drug phase